The Global Intravenous Immunoglobulin Market Size is valued at USD 12.75 billion in 2023 and is predicted to reach USD 21.38 billion by the year 2031 at a 6.70% CAGR during the forecast period for 2024-2031.
Immunoglobulins are glycoprotein molecules produced by plasma or white blood cells. Immunoglobulins serve as a crucial line of defense for the immune system, recognizing and attaching to certain antigens such as bacteria and viruses and aiding in their elimination. Intravenous immunoglobulins are immunoglobulins that are delivered intravenously. Because most patients getting immunoglobulins are in hospitals or clinical settings, intravenous immunoglobulins are the most commonly used mode of administration. This, along with the immunoglobulins' demonstrated efficacy as an effective therapy choice for various immunological illnesses and a lack of training for homecare settings, is driving the Intravenous Immunoglobulin market expansion.
However, tight government rules regarding the use of intravenous immunoglobulin products and the significant risk of side effects associated with them are projected to hamper market expansion. On the contrary, the widespread use of intravenous immunoglobulin for treating various disorders is projected to open up profitable opportunities shortly.
Recent Developments:
- In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
Competitive Landscape:
Some of the Intravenous Immunoglobulin market players are:
- Bio Products Laboratory
- Biotest
- China biologics Products Holdings
- CSL Behring
- Grifols
- Kedrion
- LFB
- Octapharma
- Shanghai RAAS Blood products
- Shire
- Others Market Players
Market Segmentation:
The Intravenous Immunoglobulin market is segmented into therapeutic area, dosage form, type of immunoglobulin, end user. based on the therapeutic area, the market is segmented into primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). The market is segmented by dosage form into liquid and lyophilized. The market is segmented by type of immunoglobulin into IgG, IgA, IgM, IgE, and IgD. The market is segmented by end users into hospitals, clinics, homecare and other end users.
The Hospital Segment Noticed Growth At A Rapid Rate
The hospital segment is projected to grow rapidly in the global Intravenous Immunoglobulin market because of the extensive hospital network. Furthermore, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders has increased the frequency of hospitalizations worldwide, increasing customer demand. Furthermore, hospitals provide prompt reimbursement, treatment, and proper care to many patients, expanding the number of patients.
The North America Intravenous Immunoglobulin Market Holds A Significant Revenue Share In The Region
The North America Intravenous Immunoglobulin market is expected to register the highest market share in revenue shortly. The major factors driving market expansion are the rising level of awareness about goods used to treat immunodeficiency illnesses, expanding clinician interest in these medicines, and rising healthcare expenditure.
Furthermore, the increasing use of IVIG therapies for illness treatment, established healthcare and research infrastructure, and the rapidly growing number of product approvals from the US FDA are expected to contribute to the region's revenue growth. In addition, Asia Pacific is projected to raise at a rapid rate in the global Intravenous Immunoglobulin market due to Emerging economies, rising healthcare spending, and a fast-expanding immunoglobulin market are all factors to consider.
Intravenous Immunoglobulin Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 12.75 Bn |
|
Revenue Forecast in 2031 |
USD 21.38 Bn |
|
Growth rate CAGR |
CAGR of 6.70% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments Covered |
By Therapeutic Area, By Dosage Form, By Type of Immunoglobulin, By End User and By Region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Shanghai RAAS Blood products, Shire and Others |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
